Terms: = Ovarian cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Diagnosis
13 results:
1. Larotrectinib in a Patient With Advanced Pleomorphic Liposarcoma of the Uterus.
Valenciaga A; Iwenofu OH; Tinoco G
J Natl Compr Canc Netw; 2021 Jul; 19(7):775-779. PubMed ID: 34340207
[TBL] [Abstract] [Full Text] [Related]
2. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract] [Full Text] [Related]
3. Circular RNA S-7 promotes ovarian cancer EMT via sponging miR-641 to up-regulate ZEB1 and mdm2.
Zhang F; Xu Y; Ye W; Jiang J; Wu C
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32667627
[TBL] [Abstract] [Full Text] [Related]
4. Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology.
Pfarr N; Darb-Esfahani S; Leichsenring J; Taube E; Boxberg M; Braicu I; Jesinghaus M; Penzel R; Endris V; Noske A; Weichert W; Schirmacher P; Denkert C; Stenzinger A
Genes Chromosomes Cancer; 2017 Oct; 56(10):758-766. PubMed ID: 28639280
[TBL] [Abstract] [Full Text] [Related]
5. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.
Köbel M; Kalloger SE; Lee S; Duggan MA; Kelemen LE; Prentice L; Kalli KR; Fridley BL; Visscher DW; Keeney GL; Vierkant RA; Cunningham JM; Chow C; Ness RB; Moysich K; Edwards R; Modugno F; Bunker C; Wozniak EL; Benjamin E; Gayther SA; Gentry-Maharaj A; Menon U; Gilks CB; Huntsman DG; Ramus SJ; Goode EL;
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1677-86. PubMed ID: 23880734
[TBL] [Abstract] [Full Text] [Related]
6. SNP285C modulates oestrogen receptor/Sp1 binding to the mdm2 promoter and reduces the risk of endometrial but not prostatic cancer.
Knappskog S; Trovik J; Marcickiewicz J; Tingulstad S; Staff AC; ; Romundstad P; Hveem K; Vatten L; Salvesen HB; Lønning PE
Eur J Cancer; 2012 Sep; 48(13):1988-96. PubMed ID: 22119201
[TBL] [Abstract] [Full Text] [Related]
7. mdm2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.
Knappskog S; Lønning PE
Oncotarget; 2011 Mar; 2(3):251-8. PubMed ID: 21436469
[TBL] [Abstract] [Full Text] [Related]
8. The mdm2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
Knappskog S; Bjørnslett M; Myklebust LM; Huijts PE; Vreeswijk MP; Edvardsen H; Guo Y; Zhang X; Yang M; Ylisaukko-Oja SK; Alhopuro P; Arola J; Tollenaar RA; van Asperen CJ; Seynaeve C; Staalesen V; Chrisanthar R; Løkkevik E; Salvesen HB; Evans DG; Newman WG; Lin D; Aaltonen LA; Børresen-Dale AL; Tell GS; Stoltenberg C; Romundstad P; Hveem K; Lillehaug JR; Vatten L; Devilee P; Dørum A; Lønning PE
Cancer Cell; 2011 Feb; 19(2):273-82. PubMed ID: 21316605
[TBL] [Abstract] [Full Text] [Related]
9. Common polymorphisms in TP53 and mdm2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
Galic V; Willner J; Wollan M; Garg R; Garcia R; Goff BA; Gray HJ; Swisher EM
Genes Chromosomes Cancer; 2007 Mar; 46(3):239-47. PubMed ID: 17171684
[TBL] [Abstract] [Full Text] [Related]
10. Diagnostic approach using the expression profiling of the P53 tumor suppressor gene and its related proteins in ovarian epithelial tumors.
Lee H; Park G; Jung JH; Ahn WS; Lee JM; Kim BK; Kang CS
Int J Gynecol Cancer; 2005; 15(3):453-61. PubMed ID: 15882169
[TBL] [Abstract] [Full Text] [Related]
11. Serous tumors of low malignant potential of the ovary-molecular pathology: part 2.
Hauptmann S; Dietel M
Virchows Arch; 2001 Jun; 438(6):539-51. PubMed ID: 11469685
[TBL] [Abstract] [Full Text] [Related]
12. Expression of heparanase, mdm2, and erbB2 in ovarian cancer.
Ginath S; Menczer J; Friedmann Y; Aingorn H; Aviv A; Tajima K; Dantes A; Glezerman M; Vlodavsky I; Amsterdam A
Int J Oncol; 2001 Jun; 18(6):1133-44. PubMed ID: 11351242
[TBL] [Abstract] [Full Text] [Related]
13. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences.
Soslow RA; Slomovitz BM; Saqi A; Baergen RN; Caputo TA
Gynecol Oncol; 2000 Dec; 79(3):430-7. PubMed ID: 11104615
[TBL] [Abstract] [Full Text] [Related]
